BA (Hons), MSc, PhD
Rebecca is Deputy Director of the newly established improvement research institute, funded by the Health Foundation. As well as leading on quantitative applied research programmes, she provides strategic leadership for the institute’s business operations (including communications, development, HR, finance and governance). Rebecca has a degree in Human Sciences from the University of Oxford, an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and a PhD in diabetes prevention from the University of Cambridge. Rebecca is currently studying for an MBA from the Open University. She has previously held research positions at the MRC Epidemiology Unit in Cambridge and the Steno Diabetes Center in Copenhagen. Rebecca currently holds a Visiting Professorship at the University of Aarhus in Denmark.
Rebecca’s main research interests relate to the primary and secondary prevention of type 2 diabetes and cardiovascular disease, and improvement of organisation and delivery of care services
Simmons RK, Borch-Johnsen K, Lauritzen T, Rutten GEHM, Sandbæk A, van den Donk M, Black JA, Tao L, Wilson ECF, Davies MJ, Khunti K, Sharp SJ, Wareham NJ, Griffin SJ. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on five-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the ADDITION-Europe study (clinical trial registration number NCT00237549). Health Technology Assessment 2016;20(64).
Echouffo-Tcheugui JB, Simmons RK, Prevost AT, Williams KM, Kinmonth A-L, Wareham NJ, Griffin SJ. Impact of population-based stepwise screening for type 2 diabetes on cardiovascular morbidity, self-rated health and health behaviour: seven year follow-up of the ADDITION-Cambridge trial. Ann Fam Med 2015; 13(2):149-157.
Long GH, Griffin SJ, Wareham NJ, Cooper AJ, Simmons RK. Healthy behaviour change and cardiovascular outcomes in newly diagnosed type 2 diabetes patients – ADDITION-Cambridge cohort study. Diab Care 2014; 37(6):1712-20.
Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Williams KM, Sargeant LA, Prevost AT, Kinmonth A-L, Wareham NJ, Griffin SJ. Effect of screening for type 2 diabetes on population mortality over 10 years: The ADDITION-Cambridge cluster – randomised controlled trial. Lancet 2012; 380:1741-1748.
Griffin SJ, Borch-Johnsen K, Davies M, Khunti K, Lauritzen T, Rutten GEHM, Sandbæk A, Sharp S, Simmons RK, van den Donk M, Wareham NJ. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
Chamnan P, Simmons RK, Khaw K-T, Wareham NJ, Griffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. British Medical Journal 2010; 340:c1693.
Her full publication list can be found here: https://www.researchgate.net/profile/Rebecca_Simmons4